Ihtsham U Haq1, Beverly M Snively2, Kathleen J Sweadner3, Cynthia K Suerken2, Jared F Cook1, Laurie J Ozelius4, Charlotte Miller1, William V McCall5, Christopher T Whitlow6, Allison Brashear1. 1. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 2. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 3. Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, USA. 4. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. 5. Department of Psychiatry and Health Behavior, Medical College of Georgia August University, Augusta, Georgia, USA. 6. Department of Radiology, Section of Neuroradiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Abstract
BACKGROUND AND OBJECTIVES: Rapid-onset dystonia-parkinsonism (RDP) is caused by mutations in the ATP1A3 gene, which codes for the α-3 subunit of the Na+ /K+ ATPase. It has been characterized by rapid-onset bulbar dysfunction, limb dystonia, bradykinesia, and a rostrocaudal spatial gradient of expression, usually after a physiologic trigger. We reexamined whether these features were in fact characteristic. METHODS: We characterized phenotypic variation within a cohort of 50 ATP1A3 mutation-positive individuals (carriers) and 44 mutation-negative family members (noncarriers). Potential participants were gathered through referral for clinical suspicion of RDP or alternating hemiplegia of childhood. Inclusion criteria were having a ATP1A3 mutation or being a family member of such an individual. RESULTS: We found RDP is underdiagnosed if only "characteristic" patients are tested. Rapid onset and bulbar predominance were not universally present in carriers. Among those with at least mild symptoms of dystonia, rostrocaudal severity gradient was rare (7%). Symptoms began focally but progressed to be generalized (51%) or multifocal (49%). Arm (41%) onset was most common. Arms and voice were typically most severely affected (48% and 44%, respectively). Triggers preceded onset in 77% of the participants. Rapid onset, dystonia, parkinsonism, bulbar symptoms, headaches, seizures, frontal impairment, and a history of mood disorder and a history of psychosis were more common in carriers. Approximately half of the proband mutations occurred de novo (56%). CONCLUSIONS: Our findings suggest that patients should not be excluded from ATP1A3 testing because of slow onset, limb onset, absent family history, or onset in middle adulthood. RDP should be strongly considered in the differential for any bulbar dystonia.
BACKGROUND AND OBJECTIVES: Rapid-onset dystonia-parkinsonism (RDP) is caused by mutations in the ATP1A3 gene, which codes for the α-3 subunit of the Na+ /K+ ATPase. It has been characterized by rapid-onset bulbar dysfunction, limb dystonia, bradykinesia, and a rostrocaudal spatial gradient of expression, usually after a physiologic trigger. We reexamined whether these features were in fact characteristic. METHODS: We characterized phenotypic variation within a cohort of 50 ATP1A3 mutation-positive individuals (carriers) and 44 mutation-negative family members (noncarriers). Potential participants were gathered through referral for clinical suspicion of RDP or alternating hemiplegia of childhood. Inclusion criteria were having a ATP1A3 mutation or being a family member of such an individual. RESULTS: We found RDP is underdiagnosed if only "characteristic" patients are tested. Rapid onset and bulbar predominance were not universally present in carriers. Among those with at least mild symptoms of dystonia, rostrocaudal severity gradient was rare (7%). Symptoms began focally but progressed to be generalized (51%) or multifocal (49%). Arm (41%) onset was most common. Arms and voice were typically most severely affected (48% and 44%, respectively). Triggers preceded onset in 77% of the participants. Rapid onset, dystonia, parkinsonism, bulbar symptoms, headaches, seizures, frontal impairment, and a history of mood disorder and a history of psychosis were more common in carriers. Approximately half of the proband mutations occurred de novo (56%). CONCLUSIONS: Our findings suggest that patients should not be excluded from ATP1A3 testing because of slow onset, limb onset, absent family history, or onset in middle adulthood. RDP should be strongly considered in the differential for any bulbar dystonia.
Authors: Allison Brashear; William B Dobyns; Patricia de Carvalho Aguiar; Michel Borg; C J M Frijns; Seema Gollamudi; Andrew Green; João Guimaraes; Bret C Haake; Christine Klein; Gurutz Linazasoro; Alexander Münchau; Deborah Raymond; David Riley; Rachel Saunders-Pullman; Marina A J Tijssen; David Webb; Jacek Zaremba; Susan B Bressman; Laurie J Ozelius Journal: Brain Date: 2007-02-04 Impact factor: 13.501
Authors: Patricia de Carvalho Aguiar; Kathleen J Sweadner; John T Penniston; Jacek Zaremba; Liu Liu; Marsha Caton; Gurutz Linazasoro; Michel Borg; Marina A J Tijssen; Susan B Bressman; William B Dobyns; Allison Brashear; Laurie J Ozelius Journal: Neuron Date: 2004-07-22 Impact factor: 17.173
Authors: W B Dobyns; L J Ozelius; P L Kramer; A Brashear; M R Farlow; T R Perry; L E Walsh; E J Kasarskis; I J Butler; X O Breakefield Journal: Neurology Date: 1993-12 Impact factor: 9.910
Authors: Eleni Panagiotakaki; Elisa De Grandis; Michela Stagnaro; Erin L Heinzen; Carmen Fons; Sanjay Sisodiya; Boukje de Vries; Christophe Goubau; Sarah Weckhuysen; David Kemlink; Ingrid Scheffer; Gaëtan Lesca; Muriel Rabilloud; Amna Klich; Alia Ramirez-Camacho; Adriana Ulate-Campos; Jaume Campistol; Melania Giannotta; Marie-Laure Moutard; Diane Doummar; Cecile Hubsch-Bonneaud; Fatima Jaffer; Helen Cross; Fiorella Gurrieri; Danilo Tiziano; Sona Nevsimalova; Sophie Nicole; Brian Neville; Arn M J M van den Maagdenberg; Mohamad Mikati; David B Goldstein; Rosaria Vavassori; Alexis Arzimanoglou Journal: Orphanet J Rare Dis Date: 2015-09-26 Impact factor: 4.123
Authors: Mary E Moya-Mendez; Lyndsay L Madden; Kathryn W Ruckart; Karen M Downes; Jared F Cook; Beverly M Snively; Allison Brashear; Ihtsham U Haq Journal: J Clin Neurosci Date: 2020-10-05 Impact factor: 1.961
Authors: Aikaterini Vezyroglou; Rhoda Akilapa; Katy Barwick; Saskia Koene; Catherine A Brownstein; Muriel Holder-Espinasse; Andrew E Fry; Andrea H Németh; George K Tofaris; Eleanor Hay; Imelda Hughes; Sahar Mansour; Santosh R Mordekar; Miranda Splitt; Peter D Turnpenny; Demetria Demetriou; Tamara T Koopmann; Claudia A L Ruivenkamp; Pankaj B Agrawal; Lucinda Carr; Virginia Clowes; Neeti Ghali; Susan Elizabeth Holder; Jessica Radley; Alison Male; Sanjay M Sisodiya; Manju A Kurian; J Helen Cross; Meena Balasubramanian Journal: Neurology Date: 2022-07-18 Impact factor: 11.800